How Goff was paid
$5.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Brian GoffChief Executive Officer | $846,864 | — | $1,291,680 | $2,627,252 | $592,804 | $11,789 | $5,370,389 |
| Cecilia JonesChief Financial Officer | $535,085 | — | $924,379 | $802,008 | $240,789 | $15,961 | $2,518,222 |
| James BurnsChief Legal Officer | $527,275 | — | $786,898 | $802,008 | $237,274 | $15,961 | $2,369,416 |
| Sarah Gheuens, M.D., Ph.D.Chief Medical Officer, Head of Research & Development | $601,060 | — | $397,440 | $802,008 | $270,478 | $15,694 | $2,086,680 |
| Krishnan Viswanadhan, Pharm.DChief Corporate Development & Strategy Officer | $433,125 | $250,000 | $824,985 | $1,048,532 | $236,250 | $12,134 | $2,805,026 |
What changed and why
- $5.4MBrian Goff received total compensation of $5,370,389 in 2025.
- $54.0MWorldwide revenue reached $54.0 million in 2025 compared to $36.5 million for 2024.
- 94%Approximately 94% of the votes cast supported the say-on-pay proposal in 2025.
- 100%The board determined an overall annual cash incentive achievement of 100% for 2025.
- AQVESME was approved by the FDA in December 2025 for certain anemias.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.